Ahmed Elmaraezy

Mr. Ahmed Elmaraezy


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Oral Oncology
Verified
Journal Article
Closed access
SASana Maher Hasan Aghbari
Sana Maher Hasan Aghbari
Abdelrahman AbushoukAbdelrahman Abushouk
Abdelrahman Abushouk
AAAttia Attia
Attia Attia
AEAhmed Elmaraezy
Ahmed Elmaraezy
AMAmr Menshawy
Amr Menshawy
EAEman Magdy Ahmed
Eman Magdy Ahmed

5 July 2016 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
MMMostafa Ebraheem Morra
Mostafa Ebraheem Morra
AEAhmed Elgebaly
Ahmed Elgebaly
AEAhmed Elmaraezy
Ahmed Elmaraezy
AKAdham M. Khalil
Adham M. Khalil
AAAhmed M. A. Altibi
Ahmed M. A. Altibi
KHKenji Hirayama
Kenji Hirayama
Several different interventions have been examined to alleviate pain and reduce frequency of trigeminal neuralgia (TN) paroxysms. However, some patients continue to have persistent or recurrent painful attacks. Using a systematic review and meta-analysis approach, we aimed to synthesize evidence from published randomized controlled trials (RCTs) regarding safety and efficacy of botulinum toxin type A (BTX-A) as a possible emerging choice of treatment for TN. We conducted an electronic search in 10 databases/electronic search engines to access relevant publications. All articles in all languages reporting RCTs on the efficacy and safety of BTX-A in the treatment of TN were included for systematic review and meta-analysis. A total of four RCTs (n = 178) were identified for final meta-analysis. The overall effect favored BTX-A versus placebo in terms of proportion of responders (risk ratio RR = 2.87, 95 % confidence interval CI [1.76, 4.69], p <0.0001) with no significant detected heterogeneity (p = 0.31; I2 = 4 %). Paroxysms frequency per day was significantly lower for BTX-A group (mean difference MD = -29.79, 95 % CI [-38.50,–21.08], p <0.00001) with no significant heterogeneity (p = 0.21; I2 = 36 %). Despite limited data, our results suggest that BTX-A may be an effective and safe treatment option for patients with TN. Further larger and well-designed RCTs are encouraged to translate these findings into better clinical outcome and better quality of life for TN patients.

13 May 2017 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
AEAhmed Elmaraezy
Ahmed Elmaraezy
MMMostafa Ebraheem Morra
Mostafa Ebraheem Morra
AMAbdelrhman Tarek Mohammed
Abdelrhman Tarek Mohammed
AAAhmed Al‐Habbaa
Ahmed Al‐Habbaa
AEAhmed Elgebaly
Ahmed Elgebaly
KHKenji Hirayama
Kenji Hirayama

6 April 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EMEvaristus Chibunna Mbanefo
Evaristus Chibunna Mbanefo
AAAli Mahmoud Ahmed
Ali Mahmoud Ahmed
ATAfaf Titouna
Afaf Titouna
AEAhmed Elmaraezy
Ahmed Elmaraezy
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
KHKenji Hirayama
Kenji Hirayama
Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency overlaps with malaria endemicity although it predisposes carriers to hemolysis. This fact supports the protection hypothesis against malaria. The aim of this systematic review is to assess the presence and the extent of protective association between G6PD deficiency and malaria. Thirteen databases were searched for papers reporting any G6PD alteration in malaria patients. Twenty-eight of the included 30 studies were eligible for the meta-analysis. Results showed absence of negative association between G6PD deficiency and uncomplicated falciparum malaria (odds ratio (OR), 0.77; 95% confidence interval (CI), 0.59–1.02; p = 0.07). However, this negative association happened in Africa (OR, 0.59; 95% CI, 0.40–0.86; p = 0.007) but not in Asia (OR, 1.24; 95% CI, 0.96–1.61; p = 0.10), and in the heterozygotes (OR, 0.70; 95% CI, 0.57–0.87; p = 0.001) but not the homo/hemizygous (OR, 0.70; 95% CI, 0.46–1.07; p = 0.10). There was no association between G6PD deficiency and total severe malaria (OR, 0.82; 95% CI, 0.61–1.11; p = 0.20). Similarly, there was no association with other malaria species. G6PD deficiency can potentially protect against uncomplicated malaria in African countries, but not severe malaria. Interestingly, this protection was mainly in heterozygous, being x-linked thus related to gender.

4 April 2017 in BMC Neurology
Verified
Journal Article
Open access
PDF file
Abdelrahman AbushoukAbdelrahman Abushouk
Abdelrahman Abushouk
AEAhmed Elmaraezy
Ahmed Elmaraezy
AAAmro Aglan
Amro Aglan
RSReham Salama
Reham Salama
SFSamar Fouda
Samar Fouda
AAAmmar M. AlSafadi
Ammar M. AlSafadi
Alzheimer’s disease (AD) is a globally prevalent neurodegenerative condition, clinically characterized by progressive memory loss and gradual impairment of cognitive functions. Bapineuzumab is a fully humanized monoclonal antibody that binds to neurotoxic amyloid proteins in the brain, enhancing their clearance. We performed this systematic review and meta-analysis to evaluate the safety and efficacy of bapineuzumab in patients with mild to moderate Alzheimer’s disease. We performed a web-based literature search of PubMed, Ovid, EBSCO, Scopus, Embase, Cochrane CENTRAL, and web of science using the relevant keywords. Data were extracted from eligible records and pooled as mean difference (MD) or risk ratio (RR) values with their 95% confidence interval (CI), using Review Manager software (version 5.3 for windows). Heterogeneity was measured by Chi-square and I-square tests. The pooled effect estimate from six randomized clinical trials (n = 2380) showed that bapineuzumab significantly reduced the cerebrospinal fluid concentration of phosphorylated tau proteins (Standardized MD = −5.53, 95% CI [−8.29, −2.76]). However, the bapineuzumab group was not superior to the placebo group in terms of change from baseline in Alzheimer’s disease assessment scale (ADAS)-Cog11 (MD = 0.14, 95% CI [−0.72, 0.99]), disability assessment for dementia (DAD) scale (MD = 1.35, 95% CI [−1.74, 4.43]), and mini-mental state examination (MMSE) scores (MD = 0.08, 95% CI [−0.31, 0.47]). Regarding safety, bapineuzumab increased the risk of serious treatment-emergent adverse events (RR = 1.18, 95% CI [1.02, 1.37]) and cerebral vasogenic edema (RR = 40.88, 95% CI [11.94, 135.95]). All bapineuzumab doses (0.15, 0.5, 1, and 2 mg/kg) were similar to placebo in terms of change from baseline in ADAS-cog11, DAD, and MMSE scores, except for the 0.15 mg/kg dose, which caused a significant worsening on the ADAS-cog11 scale (MD = 5.6, 95% CI [0.22, 10.98]). Considering the lack of clinical efficacy, combined with the significant association with serious adverse events, bapineuzumab should not be used to treat patients with mild to moderate AD. Future studies should investigate the effect of combining bapineuzumab with other therapeutic strategies and reevaluate the efficacy of targeting amyloid β proteins in AD therapy.

22 November 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MMMostafa Ebraheem Morra
Mostafa Ebraheem Morra
NKNguyen Dang Kien
Nguyen Dang Kien
AEAhmed Elmaraezy
Ahmed Elmaraezy
OAOmar Ayman M. Abdelaziz
Omar Ayman M. Abdelaziz
AEAhmed Lotfy Elsayed
Ahmed Lotfy Elsayed
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
Leukemia is the most commonly diagnosed childhood cancer, although its etiology is still largely unknown. Growing evidence supports a role for infection in the etiology of acute lymphocytic leukemia (ALL), and the involvement of the immune system suggests that vaccination may also play a role. However, the findings presented in the published literature are inconsistent. Therefore, we conducted a PRISMA systematic review and meta-analysis. 14 studies were identified and meta-analyzed. Vaccinations studied comprised Bacillus Calmette-Guérin (BCG) vaccine, Triple vaccine, Hepatitis B vaccine (HBV), Polio, Measles, Rubella, Mumps, trivalent MMR vaccine and Haemophilus influenza type B (HiB) vaccine. We observed a protective association between any vaccination in the first year of life and risk of childhood leukemia (summary odds ratio (OR) 0.58 [95% confidence interval (CI) 0.36–0.91]). When individual vaccines were analysed, some evidence of an association was seen only for BCG (summary OR 0.73 [95% CI 0.50–1.08]). In conclusion, early vaccination appears to be associated with a reduced risk of childhood leukemia. This finding may be underpinned by the association observed for BCG. Given the relatively imprecise nature of the results of this meta-analysis, our findings should be interpreted cautiously and replicated in future studies.